Publicacións en colaboración con investigadores/as de Fundación Hospital Alcorcón (13)

2019

  1. Frequency of clonal mast cell diseases among patients presenting with anaphylaxis: A prospective study in 178 patients from 5 tertiary centers in Spain

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 7, Núm. 8, pp. 2924-2926.e1

  2. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

2017

  1. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)

    Haematologica, Vol. 102, Núm. 2, pp. 235-245

2016

  1. Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia

    Leukemia

  2. Genome-Wide Pathway Analysis Identifies Genetic Pathways Associated with Psoriasis

    Journal of Investigative Dermatology, Vol. 136, Núm. 3, pp. 593-602

  3. Urine metabolome profiling of immune-mediated inflammatory diseases

    BMC Medicine, Vol. 14, Núm. 1

2015

  1. A deletion at adamts9-magi1 locus is associated with psoriatic arthritis risk

    Annals of the Rheumatic Diseases, Vol. 74, Núm. 10, pp. 1875-1881

2014

  1. Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

    Blood, Vol. 123, Núm. 12, pp. 1864-1869

2012

  1. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes

    Human Molecular Genetics, Vol. 21, Núm. 20, pp. 4549-4557

2011

  1. Evaluation of basophil activation in mastocytosis with hymenoptera venom anaphylaxis

    Cytometry Part B - Clinical Cytometry, Vol. 80 B, Núm. 3, pp. 167-175

2010

  1. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era

    European Journal of Haematology, Vol. 85, Núm. 4, pp. 321-328

  2. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms

    Journal of Allergy and Clinical Immunology, Vol. 125, Núm. 6

2008

  1. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis

    Journal of Allergy and Clinical Immunology, Vol. 121, Núm. 2, pp. 519-526